MetaVia Inc. — Director's Dealing 2023

Jul 28, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NeuroBo Pharmaceuticals, Inc. (NRBO)
CIK: 0001638287
Period of Report: 2023-07-27

Reporting Person: Kim Na Yeon (Director, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-07-27	Common Stock	A	87500	—	Acquired	88959	Direct
2023-07-27	Common Stock	A	12500	—	Acquired	101459	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	4671	Indirect
Common Stock	96351	Indirect
Common Stock	37373	Indirect
Common Stock	62159	Indirect

Footnotes

F1: Represents a grant of restricted stock units ("RSUs") issued to the reporting person under the Issuer's 2022 Equity Incentive Plan.

F2: 50% of the RSUs vested immediately, and the remainder will vest in two equal installments on each subsequent anniversary of the date of grant, subject to continuing service.

F3: The share amount has been adjusted to reflect the reverse stock split effective on September 12, 2022 whereby each thirty shares issued and outstanding prior to the split were combined and converted into one share of common stock.

F4: Vests on the earlier of July 27, 2024 or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, subject to continuing service.

F5: Ms. Kim is the Chief Executive Officer of E&Investment, Inc., which is the sole general partner of The E&Healthcare Investment Fund II, The E&Healthcare Investment Fund No. 6 and The E&Investment Healthcare Fund No. 7, and as such, has voting and investment control over the shares held by E&Investment and its affiliated funds. The reporting person disclaims beneficial ownership of the reported securities except to the extent of her pecuniary interest therein.